Научные статьи \ Прикладные науки. Медицина. Технология \ Mедицинские науки \ Патология. Клиническая медицина \ Заболевания кроветворной системы, лимфатической системы и желез внутренней секреции. Эндокринные заболевания

Блокада ангиогенеза в терапии рака почки: механизмы, особенности и перспективы

Блокада ангиогенеза в терапии рака почки: механизмы, особенности и перспективы

Автор: Баныра О.Б., Шуляк А.В.

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Литературный обзор

Статья в выпуске: 1, 2011 года.

Бесплатный доступ

Рак почки, ангиогенез, блокада ангиогенеза, лечение, противоопухолевые препараты

Короткий адрес: https://sciup.org/142188262

IDR: 142188262

Angiogenesis inhibition in renal cell carcinoma (rcc) treatment: mechanisms, especialities and perspectives

Renal cell carcinoma is a widespread oncourologic pathology with a tendention to increasing of morbidity. Surgery is a general method of its treatment. During last years approaches to medical treatment RCC, especially metastatic forms, have changed in principle. It has been proved the major role of von-Hippel Lindau gene mutations and angiogenesis in RCC development. After perfect understanding of especialities of angiogenesis, many modern antitumoral drugs were synthesed by leading pharmaceutical companies. The mechanism of these drugs antitumor activity is based on their ability to inhibit processes of angiogenesis, cell proliferation or both. Therapy, using such kind of anticancer drugs was named targeted therapy(TT). It is possible to classify targeted drugs depending on their targets cell-localisation. The first group - vasсular endothelial growth factor (VEGF) inhibitors; the second - selective inhibitors of extracellular domains of transmembranous tyrosinkinase receptors; the third - multitargeted tyrosinkinase inhibitors; the fourth - mammalian target of rapamycin (mTOR) inhibitors. Median of overall survival (OS), using TT, sometimes mounts to 26- 29 monthes. All of targeted drugs have their own advantages (significant prolonging OS, improvement quality of life) and disadvantages (partial response, side-effects). After 10-12 monthes using TT, treatment resistance and tumor regrowth are observed. It needs to employ sequential or combined treatment. New targeted drugs and efficacy of combination TT with surgery are investigating intensively now.

Список литературы Блокада ангиогенеза в терапии рака почки: механизмы, особенности и перспективы

  • Федоренко З.П., Гулак Л.О., Горох Е.Л. та спiвав. Рак в Українi 2007-2008//Бюлетень Нацiонального канцер-реєстру України. 2009. № 10. С. 60.
  • Аксель Е.М., Давыдов М.И. Статистика злокачественных новообразований в России и странах СНГ в 2006 г.//Вест. РОНЦ им. Н.Н.Блохина РАМН. 2008. T. 19. № 2, прил. 1. С. 115-116.
  • Rini B., Small E. Biology and Clinical Development of Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma//Journal of Clinical Oncology. 2005. Vol. 23. № 5. P. 1028-1043.
  • Возiанов О.Ф., Романенко А.М., Клименко I.О. Онкоурологiя сьогоднi: досягнення, проблеми, перспективи//Онкологiя. 2006. Т. 8. № 2. C. 153-157.
  • Abdollahi A., Schwager C., Kleeff J., Esposito I., Domhan S., Peschke P., Hauser K., Hahnfeldt P., Hlatky L., Debus J., Peters J.M., Friess H., Folkman J., Huber P.E. Transcriptional network governing the angiogenic switch in human pancreatic cancer//Proc. Natl. Acad. Sci. USA. 2007. Vol. 104. P. 12890-12895.
  • Comings D. A general theory of carcinogenesis//Proc Nat Acad Sci USA. 1973. Vol. 70. P. 3324-3328.
  • Knudson A., Strong L., Anderson D. Heredity and cancer in man//Prog Med Genet. 1973. Vol. 9. P. 113-158.
  • Kaelin W. The Von Hippel-Lindau Tumor Supressor Gene and Kidney Cancer//Clinical Cancer Research. 2004. Vol. 10. P. 6290.
  • Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., Ratcliffe P.J. The tumor suppressor protein VHL targets hypoxia-inducible factor for oxygen-dependent proteolysis//Nature. 1999. Vol. 399. P. 271-275.
  • Na X., Wu G., Ryan C.K., Schoen S.R., di'Santagnese P.A., Messing E.M. Overproduction of vascular endothelial growth factor related to Von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas//J. Urol. 2003. Vol. 170. № 2, Pt.1. P. 588-592.
  • Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., Simons J.W. Overexpression of hypoxia-inducible factor 1-alpha in common human cancers and their metastases//Cancer Res. 1999. Vol. 59. № 22. P. 5830-5835.
  • Folkman J. Tumor angiogenesis: therapeutic implications//N Engl J Med. 1971. Vol. 285. P. 1182-1186.
  • Vosseler S., Mirancea N., Bohlen P., Mueller M.M., Fusenig N.E. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants//Cancer Res. 2005. Vol.65. № 4. P. 1294-1305.
  • Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., Rosenberg S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer//N. Engl. J. Med. 2003. Vol. 349. Р.427-434.
  • Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., Chevreau C., Filipek M., Melichar B., Bajetta E., Gorbunova V., Bay J.O., Bodrogi I., Jagiello-Gruszfeld A., Moore N. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, doubleblind phase III trial//Lancet. 2007. Vol. 370. P. 2103-2111.
  • D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis//Proc Nat Acad Sci USA. 1994. Vol. 91. P. 4082-4085.
  • Amato R.J., Hernandez-McClain J., Saxena S., Khan M. Lenalidomide Therapy for Metastatic Renal Cell Carcinoma//American Journal of Clinical Oncology. 2008. Vol. 31. № 3. P. 244-249.
  • Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., Barrios C.H., Salman P., Gladkov O.A., Kavina A., Zarba J.J., Chen M., McCann L., Pandite L., Roychowdhury D.F., Hawkins R.E. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial//J. Clin. Oncol. 2010. Vol. 28. P. 1061-1068.
  • Hainsworth J.D., Sosman J.A., Spigel D.R., Edwards D.L., Baughman C., Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib//J. Clin. Oncol. 2005. Vol. 23. P. 7889-7896.
  • Rixe O., Bukowski R.M., Michaelson M.D., Wilding G., Hudes G.R., Bolte O., Motzer R.J., Bycott P., Liau K.F., Freddo J., Trask P.C., Kim S., Rini B.I. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study//Lancet Oncol. 2007. Vol. 8. P. 975-984.
  • Lara P.N. Jr., Quinn D.I., Margolin K., Meyers F.J., Longmate J., Frankel P., Mack P.C., Turrell C., Valk P., Rao J., Buckley P., Wun T., Gosselin R., Galvin I., Gumerlock P.H., Lenz H.J., Doroshow J.H., Gandara D.R. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition//Clin. Cancer Res. 2003. Vol. 9. № 13. P. 4772-4781.
  • Bhargava P., Esteves B., Nosov D. Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951 a potent and selective VEGFR1, 2 and 3 kinase inhibitor in patients with renal cell carcinoma (RCC)//ASCO Annual Meeting. 2009. Abstr. № 5032.
  • Escudier B. What does the future holds in RCC?//2-nd European Multidisciplinary Meeting on Urological Cancers (EMUC). 2009. Barcelona, Spain.
  • Ratain M.J., Eisen T., Stadler W.M., Flaherty K.T., Kaye S.B., Rosner G.L., Gore M., Desai A.A., Patnaik A., Xiong H.Q., Rowinsky E., Abbruzzese J.L., Xia C., Simantov R., Schwartz B., O'Dwyer P.J. Phase II placebo-controlled randomized dicountinuation trial of sorafenib in patients with metastatic renal cell carcinoma//J. Clin. Oncol. 2006. Vol. 24. P. 2505-2512.
  • Figlin R. et al. Overall survival with sunitinib versus interferon (IFN)-alfa as firstline treatment of metastatic renal cell carcinoma (mRCC)//ASCO Meeting. 2008. Abstract 5024.
  • Eisen T., Joensuu H., Nathan P. et al. Phase II study of BAY 73-4506, a multikinase inhibitor, in previously untreated patients with metastatic or unresectable renal cell cancer (abstract #5033)//J Clin Oncol. 2009. Vol. 27. P. 242.
  • Escudier B., Negrier S., Gravis G. «Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)?» Results of the randomized TORAVA phase II trial/ASCO Annual Meeting, June 4-8, McCormic Place, Chicago, Illinois, USA//J. Clin. Oncol. 2010. P. 15. Abstract 4516.
  • Hudes G., Carducci M., Tomczak P. Temsirolimus, interferon alfa or both in advanced renal cell carcinoma//The New England Journal of Medecine. 2007. Vol. 356. P. 2271-2281.
  • Choueiri T.K., Plantade A., Elson P., Negrier S., Ravaud A., Oudard S., Zhou M., Rini B.I., Bukowski R.M., Escudier B. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma//J. Clin. Oncol. 2008. Vol. 26. № 1. P. 127-131.
  • Motzer R., Escudier B., Oudard S. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial.//The Lancet. 2008. Vol. 372. Issue 9637. P. 449-456.
  • Casciano R., Malangone E., Sherman S. et al. An indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory mRCC patients//ASCO Annual Meeting. 2010. Abstract № 4611.
  • National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Renal Cell Carcinoma, v.1.2010. (Available at http://www.nccn.org).
  • Sparks C., Guertin D. Targetting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy//Oncogene. Vol. 29. P. 3733-3744.
  • Rosen L.S., Hong D., Chap L., Kurzrock R., Garcia A., Rasmussen E. First-in-human study of AMG 386, a selective angiopoetin1/2-neutralizing peptibody, in adult patients with advanced solid tumors//J. Clin. Oncol. (Meeting Abstracts) 2007 June 20. 2007. Vol. 25. 18 suppl. Abstr. 3522.
  • Bleumer I., Knuth A., Oosterwijk E., Hofmann R., Varga Z., Lamers C., Kruit W., Melchior S., Mala C., Ullrich S., De Mulder P., Mulders P.F., Beck J. A phase II trial of chimeric monoclonal antibody WX-G250 for advanced renal cell carcinoma patients//Br. J. Cancer. 2004. Vol. 90. № 5. P. 985-990.
  • Bleumer I., Oosterwijk E., Oosterwijk-Wakka J.C., Voller M.C., Melchior S., Warnaar S.O., Mala C., Beck J., Mulders P.F. A clinical trial with chimeric monoclonal antibody WXG250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma//J. Urol. 2006. Vol. 175. № 1. P. 57-62.
  • Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S.T., Chen I., Bycott P.W., Baum C.M., Figlin R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma//N. Engl. J. Med. 2007. Vol. 356. № 2. P. 115-124.
  • Rini B., Atkins M. Resistance to targeted therapy in renal cell carcinoma.//Lancet Oncol. 2009. Vol. 10. P. 992-1000.
  • Di Lorenzo G., Buonerba C., Federico P., Rescigno P., Milella M., Ortega C., Aieta M., D'Aniello C., Longo N., Felici A., Ruggeri E.M., Palmieri G., Imbimbo C., Aglietta M., De Placido S., Mirone V. Third-line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitirs in Metastatic Renal Cell Carcinoma//European Urplogy. 2010. Accepted from: www. europeanurology.com. 17.10.2010.
  • Dutcher J., Wild D., Huges G. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib or sorafenib alone//J. Clin. Oncol. 2008. V. 26. Suppl. Abstract 5127.
  • Escudier B., Goupil M.G., Massard C., Fizazi K. Sequential therapy in renal cell carcinoma//Cancer. 2009. Vol. 115. № 10. Suppl. P. 2321-2326.
  • Bhatia S., Heath I., Puzanov W. Phase II study of recombinant Il-21 plus sorafenib as second or third line therapy for metastatic renal cell cancer [abstract 3023]//J. Clin..Oncol. 2009. Vol. 27. P. 15.
  • Logan T. A phase I/II study of AGS-003, a personalized immunotherapeutic evaluated in newly diagnosed metastatic renal cell carcinoma (mRCC) subjects//ASCO Genitourinary Cancers Symposium. 2010. Abstract. № 379.
  • Amin A., Dudek A., Logan T. A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeutic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma (RCC) in Combination with Sunitinib//J. Clin. Oncol. 2010. Vol. 28. № 15, suppl. Abstr. № 4588.
  • Kondo T., Hashimoto Y., Kobayashi H., Iizuka J., Nishikawa T., Nakano M., Tanabe K. Presurgical Targeted Therapy with Tyrosine Inhibitor for Advanced Renal Cell Carcinoma: Clinical Results and Histopathological Therapeutics Effects//Jpn. J. Clin. Oncol. 2010. Abstract. 150 DOI: 10.1093/jjco/hyq
  • Cowey C.L., Amin C., Pruthi R.S., Wallen E.M., Nielsen M.E., Grigson G., Watkins C., Nance K.V., Crane J., Jalkut M., Moore D.T., Kim W.Y., Godley P.A., Whang Y.E., Fielding J.R., Rathmell W.K. Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma//J. Cln. Oncol. 2010. Vol. 28. № 9. P. 1502-1507.
  • Powles T., Kayani I., Blanc C. The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer//ASCO Genitourinary Cancers Symposium. 2010. Abstr. № 369.
  • Jacqmin D. Timing of cytoreductive nephrectomy prior or after molecular targeted therapy?//7th Meeting of EAU Section of Oncological Urology (ESOU). 2010. P. 53.
  • Naito S., Yamamoto N., Takayama T., Muramoto M., Shinohara N., Nishiyama K., Takahashi A., Maruyama R., Saika T., Hoshi S., Nagao K., Yamamoto S., Sugimura I., Uemura H., Koga S., Takahashi M., Ito F., Ozono S., Terachi T., Naito S., Tomita Y. Prognosis of Japanese Metastatic Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463 Patients//Eur. Urol. 2010. Vol. 57. № 2. P. 317-326.
Еще
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp